MARKET

EVOK

EVOK

Evoke Pharma Inc
NASDAQ
0.5310
-0.0140
-2.57%
Closed 16:00 07/19 EDT
OPEN
0.5400
PREV CLOSE
0.5450
HIGH
0.5500
LOW
0.5070
VOLUME
8.44K
TURNOVER
0
52 WEEK HIGH
1.770
52 WEEK LOW
0.4000
MARKET CAP
4.57M
P/E (TTM)
-0.2896
1D
5D
1M
3M
1Y
5Y
1D
UPDATE 2-Bookmaker Evoke warns on profit after weak online revenue growth
British betting firm Evoke warns on profit after weak online revenue growth in the second quarter. Shares in the company fell more than 8% in early trade. Evoke's brands include William Hill, 888 and Mr Green. The company said first-half earnings would miss expectations.
Reuters · 3d ago
Weekly Report: what happened at EVOK last week (0708-0712)?
Weekly Report · 6d ago
Weekly Report: what happened at EVOK last week (0701-0705)?
Weekly Report · 07/08 11:38
Weekly Report: what happened at EVOK last week (0624-0628)?
Weekly Report · 07/01 11:39
Weekly Report: what happened at EVOK last week (0617-0621)?
Weekly Report · 06/24 11:48
Evoke Pharma appoints Mark Kowieski as CFO
Healthcare Evoke Pharma appoints Mark Kowieski as CFO in May. The company will report full results for sales in the second quarter in August. EVOK +4.026% premarket to $0.4909 in Monday's trading.
Seeking Alpha · 06/17 13:03
Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMotI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer. Evoke Pharma, Inc. Is a specialty pharmaceutical company focused on treatments for gastrointestinal diseases.
Benzinga · 06/17 12:41
EVOKE PHARMA INC: PROMOTION OF MARK KOWIESKI TO ROLE OF CHIEF FINANCIAL OFFICER
Reuters · 06/17 12:30
More
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Webull offers Evoke Pharma Inc stock information, including NASDAQ: EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.